

Clinical Trial Protocol

Iranian Registry of Clinical Trials

30 Jun 2026

Efficacy of Aspirin in the treatment of schizophrenia

Protocol summary

Summary

The objective of this triple blind randomized clinical trial research is the study of Aspirin efficacy in the treatment of schizophrenia. In this study, 60 schizophrenic patients meeting inclusion and exclusion criteria are randomly assigned into intervention or control group. The patients of intervention group receive Aspirin 1000mg/day while in control group they receive placebo with the same dose and form. PANSS scores will be assessed and compared between groups.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201108197373N1**

Registration date: **2011-10-17, 1390/07/25**

Registration timing: **prospective**

Last update:

Update count: **0**

Registration date

2011-10-17, 1390/07/25

Registrant information

Name

Hamidreza Jamilian

Name of organization / entity

Arak University Of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 86 1222 5758

Email address

jamilian.hr@arakmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Arak University Of Medical Sciences Vice President Of

Education And Research

Expected recruitment start date

2011-10-23, 1390/08/01

Expected recruitment end date

2012-05-21, 1391/03/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Efficacy of Aspirin in the treatment of schizophrenia

Public title

Efficacy of Aspirin in the treatment of schizophrenia

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: age range 15-55, diagnosis of schizophrenia according to DSM4-TR criteria and clinical interview by psychiatrist, signing written informed consent, a score of at least 60 in PANSS Exclusion criteria: pregnancy, substance abuse, severe physical disease such as kidney disease, coagulation disorders, GI disorders such as peptic ulcer, contraindications of Aspirin and inhibitors of proton pump

Age

From **15 years** old to **55 years** old

Gender

Both

Phase

1

Groups that have been masked

No information

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Triple blinded

Blinding description**Placebo**

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Arak University Of Medical Sciences

Street address

Arak University Of Medical Sciences,Basij Square,Sardasht,Arak

City

Arak

Postal code**Approval date**

2011-07-06, 1390/04/15

Ethics committee reference number

1-110-90

Health conditions studied**1****Description of health condition studied**

Schizophrenia

ICD-10 code

F20

ICD-10 code description

Schizophrenia, schizotypal and delusional disorders.

Primary outcomes**1****Description**

PANSS

Timepoint

Before invention and every two weeks

Method of measurement

Clinical examination

Secondary outcomes**1****Description**

Extrapyramidal and GI side effect

Timepoint

Before invention and every two weeks

Method of measurement

Clinical examination

Intervention groups**1****Description**

Intervention group receive an atypical antipsychotic plus Aspirin 1000mg/day for 8 weeks

Category

Treatment - Drugs

2**Description**

Control group receive an atypical antipsychotic plus plasebo for 8 weeks (with the same dose and shape).

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Amirkabir Hospital

Full name of responsible person

Dr Hamireza Jamilian

Street address

Amirkabir Hospital

City

Arak

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Arak University Of Medical Sciences

Full name of responsible person

Dr. Ashtiany

Street address

Basij square,Sardasht,University of medical sciences,Arak

City

Arak

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Arak University Of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

empty

Person responsible for general inquiries**Contact****Person responsible for scientific inquiries****Contact****Name of organization / entity**

Arak University of Medical Sciences

Full name of responsible person

Dr Hamidreza Jamilian

Position

Board Of Psychiatry

Other areas of specialty/work**Street address**

Arak University of Medical Sciences, Basij Square,
Sardasht

City

Arak

Postal code

3819691187

Phone

+98 86 1222 5758

Fax

+98 86 1313 2518

Email

Jamilian.Hr@arakmu.ac.ir

Web page address**Person responsible for updating data****Contact****Sharing plan****Deidentified Individual Participant Data Set (IPD)**

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty